Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00933504
First received: July 3, 2009
Last updated: September 13, 2010
Last verified: September 2010

July 3, 2009
September 13, 2010
June 2009
July 2009   (final data collection date for primary outcome measure)
Evaluation of the absence of primary and accumulated dermical irritability and dermical sensitivity by using International Contact Dermatitis Research Group (ICDRG) scale [ Time Frame: from the treatment start to the end of the study (treatment duration 6 weeks) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00933504 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral
Study for Dermatological Evaluation of Topic Compatibility. Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd PH_DESILSTY_FL (Lactic Acid).

Primary Objective:

To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd PHDESILSTYFL.

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hygiene
Drug: LACTIC ACID(ND)
Treatment duration: 6 weeks.
Experimental: Dermacyd Silver Floral (Lactic Acid)
Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
Intervention: Drug: LACTIC ACID(ND)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
55
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Phototype Skin I,II, III e IV Integral skin test in the region
  • Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

  • Lactation or pregnancy
  • Use of Antiinflammatory 30 days and/or immunossupression drugs for until 3 months before volunteers selection
  • Disease which can cause immunosuppresion, such as diabetes, HIV
  • Use of Antihistamines 30 days before selection
  • Personnel history of atopy
  • History of sensitivity or irritation for topic products
  • Cutaneous active disease (local and/or general) which can modify the study results
  • Use of new drugs and/or cosmetics during the study
  • Cutaneous reactive
  • Previous participation in studies using the same product in test
  • Volunteer which has immunodeficiency congenital or acquired
  • Relevant history or confirmation of alcohol or other drugs abuse
  • Intolerance detected or suspected for some component of the sample tested
  • Medecin or sponsor employees or their close family

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Both
18 Years to 60 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Brazil
 
NCT00933504
LACAC_L_04804
Not Provided
Medical Affairs Study Director, sanofi-aventis
Sanofi
Not Provided
Study Director: Jaderson Lima Sanofi
Sanofi
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP